ATE354364T1 - Verwendung von at-1 rezeptorantagonisten oder at- 2 rezeptormodulatoren zur behandlung von erkrankungen, die mit einer erhöhung an at-1 oder at-2 rezeptoren verbunden sind - Google Patents

Verwendung von at-1 rezeptorantagonisten oder at- 2 rezeptormodulatoren zur behandlung von erkrankungen, die mit einer erhöhung an at-1 oder at-2 rezeptoren verbunden sind

Info

Publication number
ATE354364T1
ATE354364T1 AT99964665T AT99964665T ATE354364T1 AT E354364 T1 ATE354364 T1 AT E354364T1 AT 99964665 T AT99964665 T AT 99964665T AT 99964665 T AT99964665 T AT 99964665T AT E354364 T1 ATE354364 T1 AT E354364T1
Authority
AT
Austria
Prior art keywords
receptors
increase
treatment
receptor
diseases associated
Prior art date
Application number
AT99964665T
Other languages
English (en)
Inventor
Gillian Rosemary Bullock
Gasparo Marc De
Sabina Maria Ganter
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26152118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE354364(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP98811258A external-priority patent/EP1013273A1/de
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE354364T1 publication Critical patent/ATE354364T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99964665T 1998-12-23 1999-12-22 Verwendung von at-1 rezeptorantagonisten oder at- 2 rezeptormodulatoren zur behandlung von erkrankungen, die mit einer erhöhung an at-1 oder at-2 rezeptoren verbunden sind ATE354364T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98811258A EP1013273A1 (de) 1998-12-23 1998-12-23 Verwendung von AT-1 Rezeptorantagonisten oder AT-2 Rezeptormodulatoren zur Behandlung von Erkrankungen, die mit einer Erhöhung an AT-1 oder AT-2 Rezeptoren verbunden sind
EP98811257 1998-12-23

Publications (1)

Publication Number Publication Date
ATE354364T1 true ATE354364T1 (de) 2007-03-15

Family

ID=26152118

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05013209T ATE524176T1 (de) 1998-12-23 1999-12-22 Valsartan tablette
AT99964665T ATE354364T1 (de) 1998-12-23 1999-12-22 Verwendung von at-1 rezeptorantagonisten oder at- 2 rezeptormodulatoren zur behandlung von erkrankungen, die mit einer erhöhung an at-1 oder at-2 rezeptoren verbunden sind

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT05013209T ATE524176T1 (de) 1998-12-23 1999-12-22 Valsartan tablette

Country Status (26)

Country Link
EP (3) EP1140071B1 (de)
JP (2) JP2002533390A (de)
KR (1) KR100646716B1 (de)
CN (2) CN1636561A (de)
AT (2) ATE524176T1 (de)
AU (4) AU3043000A (de)
BR (1) BR9916576A (de)
CA (2) CA2351357A1 (de)
CY (2) CY1106581T1 (de)
CZ (2) CZ297795B6 (de)
DE (1) DE69935249T2 (de)
DK (2) DK1140071T3 (de)
ES (2) ES2281978T3 (de)
HK (1) HK1038888B (de)
HU (1) HUP0104780A3 (de)
ID (1) ID29856A (de)
IL (5) IL143233A0 (de)
NO (2) NO328775B1 (de)
NZ (3) NZ511938A (de)
PL (1) PL199100B1 (de)
PT (2) PT1588706E (de)
RU (3) RU2271809C2 (de)
SI (2) SI1588706T1 (de)
SK (1) SK9132001A3 (de)
TR (7) TR200101784T2 (de)
WO (1) WO2000038676A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ522953A (en) * 2000-06-22 2005-10-28 Novartis Ag Tablet containing valsartan, microcrystalline cellulose, crospovidone, colloidal anhydrous silica/colloidal silicon dioxide and magnesium stearate
JP4972847B2 (ja) * 2000-10-11 2012-07-11 住友化学株式会社 コラーゲン蓄積抑制剤
WO2002083127A1 (en) * 2001-04-09 2002-10-24 Tokai University Educational System Protein modification-inhibitory compositions
DE60222409T2 (de) 2001-05-31 2008-09-25 Vicore Pharma Ab Trizyklische verbindungen, nützlich als angiotensin ii agonisten
EP1444988A4 (de) * 2001-11-13 2007-04-25 Takeda Pharmaceutical Krebsmittel
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
EA008063B1 (ru) * 2003-11-03 2007-02-27 Зентива А.С. Рецептура, содержащая валсартан (valsartan)
EA015108B1 (ru) 2004-12-24 2011-06-30 КРКА, д.д., НОВО МЕСТО Способ получения твердой фармацевтической композиции, содержащей валсартан
NZ555334A (en) * 2004-12-24 2010-05-28 Spinifex Pharm Pty Ltd Method of treatment or prophylaxis of a neuropathic condition using AT2 receptor antagonist
WO2006136916A2 (en) * 2005-06-20 2006-12-28 Glenmark Pharmaceuticals Limited Substantially pure micronized particles of telmisartan and pharmaceutical compositions containing same
GT200600371A (es) 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
ES2246742B1 (es) * 2005-09-06 2007-02-01 Prous Institute For Biomedical Research S.A. Uso de un derivado de imidazol.
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
CA2681708A1 (en) * 2007-03-29 2008-10-09 Alembic Limited Valsartan tablet formulations
TR200703568A1 (tr) 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formülasyonları
CN101888829A (zh) 2007-10-09 2010-11-17 诺瓦提斯公司 缬沙坦的药物制剂
KR101589317B1 (ko) * 2007-11-06 2016-01-28 노파르티스 아게 안지오텐신 수용체 길항제/차단제 (arb) 및 중성 엔도펩티다제 (nep) 억제제의 초구조에 기초한 이중-작용 제약 조성물
WO2009092052A2 (en) * 2008-01-18 2009-07-23 Massachusetts Eye And Ear Infirmary Methods and compositions for treating polyps
GB0802931D0 (en) * 2008-02-18 2008-03-26 Queen Mary & Westfield College Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal anitbody variable regions
WO2010104485A2 (en) 2009-03-11 2010-09-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Valsartan formulations
SI2536396T1 (sl) 2010-02-16 2017-01-31 KRKA, tovarna zdravil, d.d.,Novo mesto Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan
EP2455388A1 (de) 2010-11-23 2012-05-23 LanthioPep B.V. Neuartige Rezeptoragonisten von Angiotensin des Typs 2 (AT2) und Verwendungen dafür
CN102266307B (zh) * 2011-08-01 2012-10-24 海南锦瑞制药股份有限公司 一种缬沙坦胶囊及其制备方法
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
EA018867B1 (ru) * 2012-11-01 2013-11-29 Лаборатория Тютор С.А.С.И.Ф.И.А. Способ получения фармацевтической композиции и продукт способа
JP2022542437A (ja) 2019-08-02 2022-10-03 ランティオペプ ベスローテン ヴェンノーツハップ 癌の処置に用いるアンジオテンシン2型(at2)受容体アゴニスト
EP4295839A1 (de) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Kombination aus valsartan und indapamid
WO2024026528A1 (en) * 2022-08-02 2024-02-08 Dimerix Bioscience Pty Ltd Dosage regimen for the treatment of copd

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3146168A (en) * 1962-04-10 1964-08-25 Fmc Corp Manufacture of pharmaceutical preparations containing cellulose crystallite aggregates
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
ES2060737T3 (es) * 1988-02-25 1994-12-01 Yamanouchi Europ Bv Procedimiento de preparacion de un granulado farmaceutico.
SG52330A1 (en) 1989-06-14 1998-09-28 Smithkline Beecham Corp Imidazolyl-alkenoic acids
IE70593B1 (en) 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
EP0443983B1 (de) * 1990-02-19 1996-02-28 Ciba-Geigy Ag Acylverbindungen
TW201738B (de) 1990-03-20 1993-03-11 Sanofi Co
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IL99246A0 (en) 1990-09-10 1992-07-15 Abbott Lab Angiotensin ii receptor antagonists and pharmaceutical compositions containing them
WO1992005784A1 (en) * 1990-10-02 1992-04-16 Warner-Lambert Company 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists
DE4038335A1 (de) * 1990-12-01 1992-06-04 Boehringer Mannheim Gmbh Neue pyridinderivate, verfahren zu ihrer herstellung und verwendung als arzneimittel
SI9210098B (sl) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5614519A (en) * 1991-02-06 1997-03-25 Karl Thomae Gmbh (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
US5196537A (en) 1991-03-21 1993-03-23 G. D. Searle & Co. 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
GB9110636D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
DE4132632A1 (de) * 1991-10-01 1993-04-08 Bayer Ag Substituierte imidazolyl-propensaeurederivate
DE4309968A1 (de) * 1993-03-26 1994-09-29 Bayer Ag Phenylglycinamide von heterocyclisch substituierten Phenylessigsäurederivaten
HUT71331A (en) 1992-04-13 1995-11-28 Zeneca Ltd Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
WO1994013651A1 (de) 1992-12-11 1994-06-23 Ciba-Geigy Ag Benzazepinon-derivate
WO1994013642A1 (de) * 1992-12-11 1994-06-23 Ciba-Geigy Ag Substituierte benzazepinone
DE4309963A1 (de) * 1993-03-26 1994-09-29 Hubert Kamperschroer Faß zum Austragen von Gülle
FR2716882B1 (fr) * 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
DE4408497A1 (de) * 1994-03-14 1995-09-21 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
CA2184712A1 (en) * 1994-03-17 1995-09-21 Marc De Gasparo Treatment of diabetic nephropathy with valsartan
DE4432860A1 (de) * 1994-09-15 1996-03-21 Merck Patent Gmbh Imidazopyridine
JPH11513395A (ja) 1995-10-06 1999-11-16 ノバルティス・アクチエンゲゼルシャフト 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのat1−レセプターアンタゴニスト
WO1997031624A1 (en) 1996-02-27 1997-09-04 Purdue Research Foundation Liposomal delivery system
ATE230263T1 (de) * 1996-02-29 2003-01-15 Novartis Erfind Verwalt Gmbh At1 rezeptor antagonist zur anregung von apoptosis
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
DE19628617A1 (de) * 1996-07-16 1998-01-22 Basf Ag Direkttablettierhilfsmittel
KR20040078140A (ko) * 1998-07-10 2004-09-08 노파르티스 아게 발사르탄 및 칼슘 채널 차단제의 항고혈압 병용 제제
SK10522001A3 (sk) * 1999-01-26 2001-12-03 Novartis Ag Použitie antagonistov receptora angiotenzínu ii na liečenie akútneho infarktu myokardu
NZ522953A (en) * 2000-06-22 2005-10-28 Novartis Ag Tablet containing valsartan, microcrystalline cellulose, crospovidone, colloidal anhydrous silica/colloidal silicon dioxide and magnesium stearate
US20070123498A1 (en) 2003-10-17 2007-05-31 Shetty Suraj S Combination of organic compounds
JP2009018990A (ja) 2005-10-25 2009-01-29 Univ Kurume C型肝炎ウイルス由来ペプチド

Also Published As

Publication number Publication date
DK1140071T3 (da) 2007-06-04
DK1588706T3 (da) 2012-01-16
AU2003266433B2 (en) 2006-08-10
WO2000038676A1 (en) 2000-07-06
KR20010089681A (ko) 2001-10-08
CZ20012306A3 (cs) 2001-12-12
NZ587909A (en) 2012-05-25
CY1112395T1 (el) 2015-12-09
CN1304000C (zh) 2007-03-14
IL179015A0 (en) 2007-03-08
TR200605471T2 (tr) 2006-11-21
NO20013143L (no) 2001-08-16
PT1140071E (pt) 2007-05-31
ATE524176T1 (de) 2011-09-15
RU2361575C2 (ru) 2009-07-20
JP5254258B2 (ja) 2013-08-07
IL143233A (en) 2007-07-24
AU2003266433A1 (en) 2004-01-08
NO20100041L (no) 2001-08-16
HK1038888A1 (en) 2002-04-04
HUP0104780A2 (hu) 2002-04-29
CZ293257B6 (cs) 2004-03-17
EP2298298A2 (de) 2011-03-23
EP2298298A3 (de) 2011-05-11
RU2271809C2 (ru) 2006-03-20
AU2006203077A1 (en) 2006-08-10
CN1636561A (zh) 2005-07-13
BR9916576A (pt) 2001-10-02
HUP0104780A3 (en) 2002-11-28
TR200605472T1 (tr) 2007-02-21
CA2351357A1 (en) 2000-07-06
KR100646716B1 (ko) 2006-11-17
JP2010090169A (ja) 2010-04-22
NO328775B1 (no) 2010-05-10
EP1140071A1 (de) 2001-10-10
CZ297795B6 (cs) 2007-03-28
EP1588706A2 (de) 2005-10-26
CN1331590A (zh) 2002-01-16
AU2009220022B2 (en) 2011-11-03
IL179017A0 (en) 2007-03-08
NZ553010A (en) 2008-09-26
SI1140071T1 (sl) 2007-08-31
RU2008143545A (ru) 2010-05-10
TR200805741T2 (tr) 2008-10-21
RU2005124363A (ru) 2007-02-10
EP1588706B1 (de) 2011-09-14
ID29856A (id) 2001-10-18
AU2009220022A1 (en) 2009-10-15
EP1588706A3 (de) 2005-12-07
TR200200764T2 (tr) 2002-07-22
TR200101784T2 (tr) 2001-10-22
PL199100B1 (pl) 2008-08-29
TR200805740T1 (tr) 2010-06-21
CA2622805A1 (en) 2000-07-06
PT1588706E (pt) 2011-12-21
IL143233A0 (en) 2002-04-21
NO20013143D0 (no) 2001-06-22
HK1038888B (en) 2007-09-21
SK9132001A3 (en) 2002-01-07
CY1106581T1 (el) 2012-01-25
ES2281978T3 (es) 2007-10-01
TR200805275T2 (tr) 2008-09-22
CA2622805C (en) 2011-05-10
DE69935249T2 (de) 2007-10-31
SI1588706T1 (sl) 2012-01-31
DE69935249D1 (de) 2007-04-05
NZ511938A (en) 2004-02-27
EP1140071B1 (de) 2007-02-21
PL349424A1 (en) 2002-07-29
JP2002533390A (ja) 2002-10-08
IL179016A0 (en) 2007-03-08
AU3043000A (en) 2000-07-31
ES2373556T3 (es) 2012-02-06
AU2006203077B2 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
DE69935249D1 (de) Verwendung von at-1 rezeptorantagonisten oder at-2 rezeptormodulatoren zur behandlung von erkrankungen, die mit einer erhöhung an at-1 oder at-2 rezeptoren verbunden sind
MY117251A (en) Use of central cannabinoid receptor antagonists for the preparation of drugs
ZA90944B (en) Compounds which are antagonists of excitatory amino acid receptors
MXPA01012445A (es) Antagonistas de receptor metabotropico de glutamato, y su uso para tratar enfermedades del sistema nervioso central.
BR1100538A (pt) Antagonistas de vasopressina benzazepina tricìclicos
EA199700116A1 (ru) Трициклические бензазепины как антагонисты вазопрессина, способ их получения, фармкомпозиция на их основе и способ лечения
PT94181A (pt) Processo para a preparacao de heterociclos com 6 membros imidazo-condensados substituidos uteis como antagonistas de angiotensina ii
WO1999026927A3 (en) Metabotropic glutamate receptor antagonists for treating central nervous system diseases
MY131442A (en) Excitatory amino acid receptor antagonists
EA200100058A1 (ru) 4-бензилпиперидиналкилсульфоксидные гетероциклические соединения и их применение в качестве подтип-избирательных антагонистов nmda-рецепторов
EP1679313A3 (de) Heteropolycyclische Verbindungen und ihre Verwendung als Antagonisten des metabotropischen Glutamat-Rezeptors
PL331617A1 (en) Treatment of allergic response on the part of upper airways by means of a combination od histamine receptor antagonists
ATE439861T1 (de) Verfahren zur modulierung von cd200-rezeptoren
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
BG104038A (en) Use of specific antagonist of 5ht2 receptors for preparing medicines useful for treating sleep-disordered breathing
ATE330599T1 (de) Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt
DK0379308T3 (da) Fremgangsmåde til selektivt at blokere 5HT2 receptorer
DE69530600D1 (de) Verwendung von nk1-rezeptor antagonisten zur zubereitung von arzneimitteln mit kardioregulierender wirkung
IT8959368V0 (it) Immobilizzatore complesso dell'arto superiore a politrazione regolabile.
WO2002007726A8 (en) Treatment of movement disorders

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1140071

Country of ref document: EP

RZN Patent revoked